Genfit S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GNFT.PA research report →
About the company
Genfit S. A. operates as a biopharmaceutical enterprise, concentrating its efforts on discovering and developing both therapeutic candidates and diagnostic solutions for metabolic and liver-related ailments.
- CEO
- Pascal Prigent
- IPO
- 2006
- Employees
- 180
- HQ
- Loos, FR
Price Chart
- Market Cap
- $523.84M
- P/E
- -6.08
- P/S
- 7.76
- P/B
- -22.06
- EV/EBITDA
- -94.72
- Div Yield
- 0.00%
- Gross Margin
- 26.02%
- Op Margin
- -84.25%
- Net Margin
- -127.40%
- ROE
- -596.44%
- ROIC
- -41.41%
- Revenue
- $65.43M · -2.34%
- Net Income
- $-85,968,000 · -5804.58%
- EPS
- $-1.72 · -5833.33%
- Op Income
- $-58,921,000
- FCF YoY
- -287.83%
- 52W High
- $11.20
- 52W Low
- $3.05
- 50D MA
- $8.86
- 200D MA
- $6.43
- Beta
- 1.12
- Avg Volume
- 272.86K
Get TickerSpark's AI analysis on GNFT.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our GNFT.PA coverage
Recent articles, reports, and earnings notes.
No research on GNFT.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GNFT.PA report →Similar companies
Peers in the same neighborhood.